TY - JOUR
AU - Green, Ari J.
AB - Opinion EDITORIAL Autoimmune Inflammatory Astrocytopathies— Is the Spectrum Expanding? Samuel J. Pleasure, MD, PhD; Ari J. Green, MD, MCR The association of encephalitogenic antiself antibodies antigen through intact cells. Thus, it is unsurprising that these with inflammatory brain disease has grown markedly syndromes most commonly respond best to broad-spectrum therapies directed at lymphocytes. There is certainly room for with the identification of new species of autoantibodies at an ever-increasing pace over the last 25 years. The initial more targeted therapies in the future that are directed at the classification of a scattered pathogenic T cells, but therapies directed specifically at the selection of such syndromes— presence of the autoantibodies (such as plasmapheresis) show Related article mostly considered to be para- limited efficacy. In such cases, the autoantibodies are consid- neoplastic disorders—has evolved to an era with scores of iden- ered most valuable as biomarkers to help identify the syn- tified autoantibodies with a wide spectrum of phenotypes. drome and, given the frequent paraneoplastic association, to Despite improved characterization of the variety of antibod- direct search for an occult neoplasm. Prominent examples of ies associated with central nervous system (CNS) autoim- these syndromes include those associated with anti-Hu, anti- mune 
TI - Autoimmune Inflammatory Astrocytopathies—Is the Spectrum Expanding?
JF - JAMA Neurology
DO - 10.1001/jamaneurol.2024.4749
DA - 2025-01-21
UR - https://www.deepdyve.com/lp/american-medical-association/autoimmune-inflammatory-astrocytopathies-is-the-spectrum-expanding-LR5TMqXUdA
SP - 218
EP - 219
VL - 82
IS - 3
DP - DeepDyve
ER -